Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORAL Sync: Tofacitinib in Active RA on Background DMARDs
NCT00856544Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2009
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial of tofacitinib oral solution in rheumatoid arthritis (RA) (4 arms), sponsored by Pfizer. Primary endpoints: American College of Rheumatology 20% Response at 6 months, Health Assessment Questionnaire-Disability Index at 3 months and 1 more. Started May 2009; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00856544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00856544.